Kinnate Biopharma (KNTE) Stock Forecast, Price Target & Predictions
KNTE Stock Forecast
Kinnate Biopharma stock forecast is as follows: an average price target of $30.00 (represents a 1032.08% upside from KNTE’s last price of $2.65) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
KNTE Price Target
KNTE Analyst Ratings
Kinnate Biopharma Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
May 18, 2022 | Christopher Raymond | Piper Sandler | $30.00 | $9.96 | 201.20% | 1032.08% |
Kinnate Biopharma Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $2.65 | $2.65 | $2.65 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 19, 2023 | Piper Sandler | Overweight | Neutral | Downgrade |
Sep 19, 2023 | Wedbush | - | Neutral | Downgrade |
May 18, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Mar 29, 2022 | William Blair | Outperform | Outperform | Hold |
Kinnate Biopharma Financial Forecast
Kinnate Biopharma Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - |
Kinnate Biopharma EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - |
Kinnate Biopharma Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-8.95M | $-8.95M | $-12.25M | $-12.25M | $-9.42M | $-13.67M | $-13.67M | $-13.67M | $-20.03M |
High Forecast | $-8.95M | $-8.95M | $-12.25M | $-12.25M | $-9.42M | $-13.67M | $-13.67M | $-11.01M | $-16.47M |
Low Forecast | $-8.95M | $-8.95M | $-12.25M | $-12.25M | $-9.42M | $-13.67M | $-13.67M | $-16.32M | $-22.25M |
Surprise % | - | - | - | - | - | - | - | - | - |
Kinnate Biopharma SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - |
Kinnate Biopharma EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-0.19 | $-0.19 | $-0.26 | $-0.26 | $-0.20 | $-0.29 | $-0.29 | $-0.29 | $-0.42 |
High Forecast | $-0.19 | $-0.19 | $-0.26 | $-0.26 | $-0.20 | $-0.29 | $-0.29 | $-0.23 | $-0.35 |
Low Forecast | $-0.19 | $-0.19 | $-0.26 | $-0.26 | $-0.20 | $-0.29 | $-0.29 | $-0.35 | $-0.47 |
Surprise % | - | - | - | - | - | - | - | - | - |
Kinnate Biopharma Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
KNTE | Kinnate Biopharma | $2.65 | $30.00 | 1032.08% | Hold |
PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
KZR | Kezar Life Sciences | $7.09 | $17.50 | 146.83% | Buy |
ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
DSGN | Design Therapeutics | $5.32 | $9.67 | 81.77% | Buy |
SLRN | Acelyrin | $5.82 | $10.50 | 80.41% | Buy |
KROS | Keros Therapeutics | $59.95 | $102.00 | 70.14% | Buy |
BOLT | Bolt Biotherapeutics | $0.67 | $1.00 | 49.25% | Hold |
EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
PALI | Palisade Bio | $2.78 | $1.50 | -46.04% | Buy |
KNTE Forecast FAQ
Is Kinnate Biopharma a good buy?
No, according to 3 Wall Street analysts, Kinnate Biopharma (KNTE) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of KNTE's total ratings.
What is KNTE's price target?
Kinnate Biopharma (KNTE) average price target is $30 with a range of $30 to $30, implying a 1032.08% from its last price of $2.65. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Kinnate Biopharma stock go up soon?
According to Wall Street analysts' prediction for KNTE stock, the company can go up by 1032.08% (from the last price of $2.65 to the average price target of $30), up by 1032.08% based on the highest stock price target, and up by 1032.08% based on the lowest stock price target.
Can Kinnate Biopharma stock reach $4?
KNTE's average twelve months analyst stock price target of $30 supports the claim that Kinnate Biopharma can reach $4 in the near future.
What are Kinnate Biopharma's analysts' financial forecasts?
Kinnate Biopharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-50.423M (high $-47.766M, low $-53.08M), average SG&A $0 (high $0, low $0), and average EPS is $-1.07 (high $-1.014, low $-1.126). KNTE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-42.412M (high $-42.412M, low $-42.412M), average SG&A $0 (high $0, low $0), and average EPS is $-0.9 (high $-0.9, low $-0.9).